New Zealand markets closed
  • NZX 50

    11,641.85
    -12.71 (-0.11%)
     
  • NZD/USD

    0.6415
    +0.0041 (+0.64%)
     
  • NZD/EUR

    0.6082
    +0.0030 (+0.50%)
     
  • ALL ORDS

    7,503.50
    -50.50 (-0.67%)
     
  • ASX 200

    7,301.50
    -52.90 (-0.72%)
     
  • OIL

    80.34
    -0.88 (-1.08%)
     
  • GOLD

    1,797.30
    -3.80 (-0.21%)
     
  • NASDAQ

    11,994.26
    -47.63 (-0.40%)
     
  • FTSE

    7,556.23
    -2.26 (-0.03%)
     
  • Dow Jones

    34,429.88
    +34.87 (+0.10%)
     
  • DAX

    14,529.39
    +39.09 (+0.27%)
     
  • Hang Seng

    18,675.35
    -61.09 (-0.33%)
     
  • NIKKEI 225

    27,777.90
    -448.18 (-1.59%)
     
  • NZD/JPY

    86.1260
    -0.0390 (-0.05%)
     

Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference

Surface Oncology, Inc.
Surface Oncology, Inc.

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a virtual panel discussion entitled, “IOs Wide Open - Opportunity and Challenges in Immuno-Oncology” at the 2022 Wedbush PacGrow Healthcare Conference. The panel discussion will take place on Tuesday, August 9, 2022, at 8:00 am ET.

A live webcast of the discussion may be accessed by visiting the Investors & Media section of the Surface Oncology website at www.surfaceoncology.com. A replay of the webcast will be available on the company’s website following the presentation.

About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational, cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com